Polymyalgia rheumatica pathophysiology

Revision as of 17:26, 1 June 2014 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Polymyalgia Rheumatica Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polymyalgia rheumatica from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polymyalgia rheumatica pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polymyalgia rheumatica pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polymyalgia rheumatica pathophysiology

CDC on Polymyalgia rheumatica pathophysiology

Polymyalgia rheumatica pathophysiology in the news

Blogs on Polymyalgia rheumatica pathophysiology

Directions to Hospitals Treating Polymyalgia rheumatica

Risk calculators and risk factors for Polymyalgia rheumatica pathophysiology

Overview

The underlying pathophysiology of polymyalgia rheumatica (PMR) remains unknown.[1] It has been hypothesized that genetic and environmental factors are implicated, particularly due to the seasonal and geographical differences in the prevalence of this disease.[2][3][4] It has also been hypothesized that PMR is associated with infections such as parainfluenza virus type 1,[5] mycoplasma pneumoniae, chlamydia pneumoniae, and parvovirus B19.[6] In addition, histological examinations of synovial biopsies of affected individuals reveal mild synovitis with predominance of CD4 T cells and macrophages.[7]

Pathophysiology

  • PMR is a chronic inflammatory disease of the articular and periarticular structures of the cervical region, shoulder girdle and hip girdle. The cause of PMR remains unknown; however, there is evidence in the literature of possible involvement of genetic and environmental factors.[1] This hypothesis is supported by the seasonal and geographical variations of the prevalence of PMR. In fact, the prevalence of PMR is the highest among patients from northern European descent and Scandanavian countries, which suggests a genetic and/or environmental role in the pathophysiology of PMR.
  • Several genes have been reported to be involved in PMR, such as:

References

  1. 1.0 1.1 1.2 Kermani TA, Warrington KJ (2013). "Polymyalgia rheumatica". Lancet. 381 (9860): 63–72. doi:10.1016/S0140-6736(12)60680-1. PMID 23051717.
  2. Smeeth L, Cook C, Hall AJ (2006). "Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001". Ann Rheum Dis. 65 (8): 1093–8. doi:10.1136/ard.2005.046912. PMC 1798240. PMID 16414971.
  3. 3.0 3.1 Alvarez-Rodriguez L, Carrasco-Marin E, Lopez-Hoyos M, Mata C, Fernandez-Prieto L, Ruiz-Soto M; et al. (2009). "Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN*2/2 genotype with polymyalgia rheumatica". Hum Immunol. 70 (1): 49–54. doi:10.1016/j.humimm.2008.10.011. PMID 19026700.
  4. Cimmino MA, Caporali R, Montecucco CM, Rovida S, Baratelli E, Broggini M (1990). "A seasonal pattern in the onset of polymyalgia rheumatica". Ann Rheum Dis. 49 (7): 521–3. PMC 1004141. PMID 2383076.
  5. 5.0 5.1 Duhaut P, Bosshard S, Calvet A, Pinede L, Demolombe-Rague S, Dumontet C; et al. (1999). "Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes". J Rheumatol. 26 (2): 361–9. PMID 9972970.
  6. 6.0 6.1 Elling P, Olsson AT, Elling H (1996). "Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection". J Rheumatol. 23 (1): 112–9. PMID 8838518.
  7. 7.0 7.1 Meliconi R, Pulsatelli L, Uguccioni M, Salvarani C, Macchioni P, Melchiorri C; et al. (1996). "Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment". Arthritis Rheum. 39 (7): 1199–207. PMID 8670331.
  8. Haworth S, Ridgeway J, Stewart I, Dyer PA, Pepper L, Ollier W (1996). "Polymyalgia rheumatica is associated with both HLA-DRB1*0401 and DRB1*0404". Br J Rheumatol. 35 (7): 632–5. PMID 8670595.
  9. Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ (1994). "HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis". Arthritis Rheum. 37 (4): 514–20. PMID 8147928.
  10. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F; et al. (2006). "Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica". J Rheumatol. 33 (4): 703–8. PMID 16583473.
  11. Straub RH, Cutolo M (2006). "Further evidence for insufficient hypothalamic-pituitary-glandular axes in polymyalgia rheumatica". J Rheumatol. 33 (7): 1219–23. PMID 16821261.

Template:WH Template:WS